
Shanon A. Foley
Examiner (ID: 15527)
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1671, 1645, 1642, 1619, 1648 |
| Total Applications | 1508 |
| Issued Applications | 829 |
| Pending Applications | 356 |
| Abandoned Applications | 361 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18239207
[patent_doc_number] => 20230071518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => INTRANASAL mRNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 17/799118
[patent_app_country] => US
[patent_app_date] => 2021-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6889
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799118
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799118 | INTRANASAL mRNA VACCINES | Feb 14, 2021 | Abandoned |
Array
(
[id] => 16885416
[patent_doc_number] => 20210171611
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => ANTIBODY THAT BINDS TO ENVELOPE GLYCOPROTEIN OF SEVER FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS AND USE FOR SAME
[patent_app_type] => utility
[patent_app_number] => 17/171044
[patent_app_country] => US
[patent_app_date] => 2021-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171044
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/171044 | ANTIBODY THAT BINDS TO ENVELOPE GLYCOPROTEIN OF SEVER FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS AND USE FOR SAME | Feb 8, 2021 | Abandoned |
Array
(
[id] => 18765117
[patent_doc_number] => 11815513
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
[patent_app_type] => utility
[patent_app_number] => 17/166741
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 18
[patent_no_of_words] => 11453
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166741
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166741 | Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics | Feb 2, 2021 | Issued |
Array
(
[id] => 16991810
[patent_doc_number] => 20210230230
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => Soluble Forms of Hendra and Nipah Virus G Glycoprotein
[patent_app_type] => utility
[patent_app_number] => 17/161720
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17147
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161720
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/161720 | Soluble Forms of Hendra and Nipah Virus G Glycoprotein | Jan 28, 2021 | Abandoned |
Array
(
[id] => 18649760
[patent_doc_number] => 20230295581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/791678
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791678 | RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF | Jan 10, 2021 | Pending |
Array
(
[id] => 18649760
[patent_doc_number] => 20230295581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/791678
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791678 | RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF | Jan 10, 2021 | Pending |
Array
(
[id] => 18649760
[patent_doc_number] => 20230295581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/791678
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791678 | RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF | Jan 10, 2021 | Pending |
Array
(
[id] => 18649760
[patent_doc_number] => 20230295581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/791678
[patent_app_country] => US
[patent_app_date] => 2021-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791678 | RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF | Jan 10, 2021 | Pending |
Array
(
[id] => 18626728
[patent_doc_number] => 20230285534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => VIRAL VACCINE COMPOSITIONS AND METHODS OF PREPARATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/791076
[patent_app_country] => US
[patent_app_date] => 2021-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12332
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791076
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791076 | VIRAL VACCINE COMPOSITIONS AND METHODS OF PREPARATIONS THEREOF | Jan 5, 2021 | Pending |
Array
(
[id] => 16778312
[patent_doc_number] => 20210115390
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE
[patent_app_type] => utility
[patent_app_number] => 17/132440
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8936
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17132440
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/132440 | METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE | Dec 22, 2020 | Abandoned |
Array
(
[id] => 18295454
[patent_doc_number] => 20230105140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => INACTIVATED PISCINE ORTHOREOVIRUS VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/783478
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783478
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/783478 | INACTIVATED PISCINE ORTHOREOVIRUS VACCINE | Dec 14, 2020 | Issued |
Array
(
[id] => 18295454
[patent_doc_number] => 20230105140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => INACTIVATED PISCINE ORTHOREOVIRUS VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/783478
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783478
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/783478 | INACTIVATED PISCINE ORTHOREOVIRUS VACCINE | Dec 14, 2020 | Issued |
Array
(
[id] => 18241010
[patent_doc_number] => 20230073321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => PHARMACEUTICAL COMPOSITION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/784081
[patent_app_country] => US
[patent_app_date] => 2020-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7768
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784081
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/784081 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dec 10, 2020 | Pending |
Array
(
[id] => 17266423
[patent_doc_number] => 11191827
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-12-07
[patent_title] => COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/116227
[patent_app_country] => US
[patent_app_date] => 2020-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 8264
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116227
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/116227 | COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19 | Dec 8, 2020 | Issued |
Array
(
[id] => 18108092
[patent_doc_number] => 20230000972
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 97139 C140
[patent_app_type] => utility
[patent_app_number] => 17/779811
[patent_app_country] => US
[patent_app_date] => 2020-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779811
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/779811 | ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 97139 C140 | Nov 30, 2020 | Pending |
Array
(
[id] => 18051622
[patent_doc_number] => 11524993
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-13
[patent_title] => Neutralizing anti-influenza binding molecules and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/108608
[patent_app_country] => US
[patent_app_date] => 2020-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 22
[patent_no_of_words] => 41902
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 684
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108608
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/108608 | Neutralizing anti-influenza binding molecules and uses thereof | Nov 30, 2020 | Issued |
Array
(
[id] => 18101246
[patent_doc_number] => 11541115
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Triple vaccine against
[patent_app_type] => utility
[patent_app_number] => 17/104457
[patent_app_country] => US
[patent_app_date] => 2020-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 16294
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17104457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/104457 | Triple vaccine against | Nov 24, 2020 | Issued |
Array
(
[id] => 18177758
[patent_doc_number] => 20230038487
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => MODIFIED VIRAL THERAPEUTICS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/779484
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/779484 | MODIFIED VIRAL THERAPEUTICS AND USES THEREOF | Nov 18, 2020 | Pending |
Array
(
[id] => 16749953
[patent_doc_number] => 20210101962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => Mosaic Chimeric Viral Vaccine Particle
[patent_app_type] => utility
[patent_app_number] => 16/950297
[patent_app_country] => US
[patent_app_date] => 2020-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16759
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950297
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/950297 | Mosaic chimeric viral vaccine particle | Nov 16, 2020 | Issued |
Array
(
[id] => 17168872
[patent_doc_number] => 20210322542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/098449
[patent_app_country] => US
[patent_app_date] => 2020-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6345
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098449
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/098449 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE | Nov 14, 2020 | Abandoned |